Skip navigation

brans.pthalmol.oc.K. 1979. 994:481-4. Oral vitamins C and E as additional treatment in patients with acute anterior uveitis: A randomised double masked study in 145 patients. A medicine called prednisolone is usually used. If the biliary body is also involved, it is called iridocyclitis. fainter is a board-certified ophthalmologist. Diagnosing uveitis begins with taking a thorough personal and family medical history, including symptoms, and completing a physical examination that includes a thorough eye examination. DO NOT rely on complementary and alternative therapies’ AM alone to treat uveitis. She received her BA from Pomona College in Claremont, CA, and her MD from the University of Colorado in Denver, CO. no dataThere are also “snowballs,” which are inflammatory cells in the vitreous. Causes of uveitis in the general practice of ophthalmology. For more details on treatment plans, refer to treatment of uveitis . … more » Uveitis: Inflammation of the inner eye, which includes the iris, the biliary body that holds the lens of the eye; and the choroid plexus, a … more about Uveitis . The tissue and blood vessels of the choroid are important because they deliver blood to the back of the eye. However, anterior uveitis is often one of the syndromes associated with HLA-B27 .

J Am Coll nut. 2002;216:495-505. no dataThis is called infectious uveitis. It helps the eye focus by controlling the shape of the lens and it provides nutrients to keep the lens healthy. non-infectious uveitis can be caused by an eye injury or a disease somewhere else in your body. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. Medical Editor: William C. For some people, uveitis comes back again and again. Examine the epithelium for abrasions, enema, ulcers, or foreign bodies. If not diagnosed and treated promptly, complications of uveitis … more symptoms » Treatment of uveitis includes corticosteroid eye drops or ointment.

For a more detailed discussion of risk factors that could impact our future results and financial condition, I refer you to our filings with the SEC, including our annual report on Form 10-K for the year ended June 30, 2015. We undertake no obligation to update any forward-looking statement, in order to reflect events or circumstances that may arise after this conference call. With that, I’d like to turn the call over to Paul. ——————————————————————————– Paul Ashton, pSivida Corporation – President & CEO [3] ——————————————————————————– Thank you, Lori, and welcome everyone to our discussion of our FY16 full-year and fourth-quarter results and Company update. In FY16, we made substantial progress in moving forward our product development agenda, capped by significant progress in the fourth quarter. Highlights for the quarter included 12-month follow-up that maintains the favorable results from our first Phase 3 trial for Medidur in posterior segment uveitis. Opening an IND for an investigator-sponsored study of a Durasert implant for severe knee osteoarthritis. Good results from pre-clinical testing that have allowed us to identify a product candidate to treat wet age-related macular degeneration as an implant, delivering a tyrosine kinase inhibitor. We also have favorable Tethadur pre-clinical results, and a strengthened research and development program. So let’s move on to the details. We have continued to successfully move through the steps toward approval of Medidur for posterior segment uveitis, our lead development product.

For the original version including any supplementary images or video, visit

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>